Pseudobezoars: Technology Progress and New Prospects as a Medical Platform

Orly Yadid-Pecht, Martin P. Mintchev

Department of Electrical and Computer Engineering, University of Calgary, Calgary, Canada.
Department of Electrical and Computer Engineering, University of Calgary, Calgary, Canada;Department of Surgery, University of Alberta, Edmonton, Canada.

DOI: 10.4236/eng.2013.55B003                

Abstract

In recent years, pseudobezoars have been a subject of research, mainly serving as a basis for a new non-invasive alternative to obesity treatment. A pill incorporating the technology has been proven to be successful as a weight loss therapy. It enables patients to sustain a diet longer, due to an increase in the level of satiety, resulting in a smaller amount of food intake. Utilization of the technology has recently found new prospects in another organ of the GI tract, the colon. Pseudobezoar technology can be utilized as an enhanced method for colon cancer screening and also as an alternative carrier for bacterial therapy.

Keywords

Pseudobezoars; Obesity; Colon Cancer Screening; Diagnostic Device; Therapeutic Device

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	M. Mintchev, O. Yadid-Pecht and M. Fattouche, “Ingestible Implement for Weight Control,” US Patent No. 8, 389, 003, March 2013.
[2]	M. P. Mintchev, M. G. Deneva, B. I. Aminkov, M. Fattouche, O. Yadid-Pecht and R. C. Bray, “Pilot Study of Temporary Controllable Gastric Pseudobezoards for Dynamic Non-Invasive Gastric Volume Reduction,” Physiological Measurement, Vol. 31, No. 2, 2010, pp. 131-144, doi:10.1088/0967-3334/31/2/001
[3]	M. P. Mintchev, M. G. Deneva, O. Yadid-Pecht, M. Fattouche and R. C. Bray, “Temporary Controllable Gastric Pseudobezoards (Pseudofood) as an Alternative to Intragastric Balloons for the Treatment of Obesity: Results from a chronic Human Study,” Obesity Society Conference, San Diego, USA, October 2010.
[4]	M. P. Mintchev, M. G. Deneva, B. I. Aminkov, O. Yadid-Pecht, M. Fattouche and R. C. Bray, “Pilot Studies of Temporary Controllable Gastric Pseudobezoards (Pseudofood) as an Alternative to Bariatric Surgery for the Treatment of Obesity,” Gastroenterology, Vol. 138, No. 5, 2010, p. S-755. doi:10.1016/S0016-5085(10)63478-6
[5]	A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray and M. J. Thun, “Cancer Statistics,” CA: A Cancer Journal for Clinicians, Vol. 58, No. 2, 2008, pp. 71-96. doi:10.3322/CA.2007.0010
[6]	V. W. Yang, J. Lewis, T. C. Wang and A. K. Rustgi, “Colon Cancer: An Update and Future Directions,” Gastroenterology, Vol. 138, No. 6, 2010, pp. 2027-2028. doi:10.1053/j.gastro.2010.03.007
[7]	A. Weizman and G. Nguyen, “Colon Cancer Screening in 2010: An UpDate,” Minerva gastroenterologica e dietologica, Vol. 56, No. 2, 2010, pp. 181-188.
[8]	T. Morikawa, J. Kato, Y. Yamaji, R. Wada, T. Mitsushima and Y. Shiratori, “A Comparison of the Immunochemical Fecal Occult Blood Test and Total Colonoscopy in the Asymptomatic Population,” Gastroenterology, Vol. 129, No. 2, 2005, pp. 422-428.
[9]	L. Zinkin, “A Critical Review of the Classifications and Staging of Colorectal Cancer,” Diseases of the Colon and Rectum, Vol. 26, 1983, pp. 37-43. doi:10.1007/BF02554677
[10]	M. J. Turunen, K. Liewendahl, P. Partanen and H. Adlercreutz, “Immunological Detection of Faecal Occult Blood in Colorectal Cancer,” British Journal of Cancer, Vol. 49, No. 2, 1984, pp. 141-148. doi:10.1038/bjc.1984.26
[11]	J. E. Allison, I. S. Tekawa, L. J. Ransom and A. L. Adrain, “A Comparison of Fecal Occult-Blood Tests for Colorectal-Cancer Screening,” New England Journal of Medicine, Vol. 334, No. 3, 1996, pp. 155-160. doi:10.1056/NEJM199601183340304
[12]	B. Levin, D. A. Lieberman, B. McFarland, et al., “Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline From the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology,” Gastroenterology, Vol. 134, No. 5, 2008, pp. 1570-1595. doi:10.1053/j.gastro.2008.02.002
[13]	B. M. Levin, “Promoting Early Detection Tests for Colorectal Carcinoma and Adenoma Polyps,” Cancer, Vol. 98, No. 8, 2002, pp. 1618-1628. doi:10.1002/cncr.10890
[14]	J. S. Mandel, T. R. Church, J. H. Bond, et al., “The Effect of Fecal Occult-Blood Screening on the Incidence of Colorectal Cancer,” New England Journal of Medicine, Vol. 343, No. 22, 2000, pp. 1603-1607. doi:10.1056/NEJM200011303432203
[15]	S. H. Woolf et al., “A Smarter Strategy? — Reflections on Fecal DNA Screening for Colorectal Cancer,” New England Journal of Medicine, Vol. 351, 2004, pp. 2755-2758. doi:10.1056/NEJMe048259
[16]	K. Song, A. M. Fendric and U. Ladabaum,” Fecal DNA Testing Compared with Conventional Colorectal Cancer Screening Methods: A Decision Analysis,” Journal of Gastroenterology, Vol. 126, No. 5, 2004, pp. 1270-1279. doi:10.1053/j.gastro.2004.02.016
[17]	A. D. Müller, A. Sonnenberg, “Protection by Endoscopy Against Death From Colorectal Cancer: A Case-Control Study Among Veterans,” Archives of Internal Medicine, Vol. 155, No. 16, 1995, pp. 1741-1748. doi:10.1001/archinte.1995.00430160065007
[18]	D. S. Weinberg, “Colonoscopy: What Does It Take to Get It ‘Right’?” J. Ann. Intern Med, Vol. 154, No. 1, 2011, pp. 68-69.
[19]	G. Minoli, G. Meucci, A. Prada, et al., “Quality Assurance and Colonoscopy,” Endoscopy, Vol. 31, No. 7, 1999, pp. 522-527. doi:10.1055/s-1999-54
[20]	W. El-Matary, “Wireless Capsule Endoscopy: Indications, Limitations and Future Challenges,” Journal of Pediatric Gastroenterology Nutrition, Vol. 46, No. 1, 2008, pp. 4-12. doi:10.1097/01.mpg.0000304447.69305.cc
[21]	ASGE Technology Commitee, “Capsule Endoscopy of the Colon,” J Gastrointest Endosc, Vol. 68, No. 4, 2008, pp. 621-623.
[22]	R. Eliakim, Z. Fireman, I. M. Gralnek et al., “Evaluation of the Pill Cam Colon Capsule in the Detection of Colonic Pathology: Results of the First Multicenter, Prospective, Comparative Study,” Endoscopy, Vol. 38, No. 10, 2006, pp. 963-970. doi:10.1055/s-2006-944832
[23]	D. Lieberman, “Progress and Challenges in Colorectal Cancer Screening and Surveillance,” Gastroenterology, Vol. 138, No. 6, 2010, pp. 2115-2126. doi:10.1053/j.gastro.2010.02.006
[24]	K. N. C. Hin, O. Yadid-Pecht and M. Mintchev, “E-Stool: Self-Stabilizng Capsule for Colonic Imaging,” in Proceedings of the 20th Int. Symposium on Neurogastroenterology and Motility, July 3, 2005, pp. 86-90.
[25]	J. B. Pilz, S. Portmann, P. Shajan, CH. Beglinger and L. Degen, “Colon Capsule Endoscopy Compared to Conventional Colonoscopy under Routine Screening Conditions,” J BMC Gastroenterology, Vol. 10, No. 66, 2010.
[26]	D. Filip, O. Yadid-Pecht, C. N. Andrews and M. P. Mintchev, “Self-Stabilizing Colonic Capsule Endoscopy: Pilot Study of Acute Canine Models,” IEEE Transactions on Medical Imaging. Vol. 30, No. 12, 2011, pp. 2115-2125.
[27]	P. J. Pickhardt et al., “Computed Tomographic Virtual Colonoscopy to Screen for Colorectal Neoplasia in Asymptomatic Adults,” New England Journal of Medicine, Vol. 349, 2003, pp. 2191-2200. doi:10.1056/NEJMoa031618
[28]	P. Schoenfield, “The Preferred Test for CRC Prevention is not Colonoscopy In the future,” AGA Pespectives, Vol. 9, No. 1, March 2013.
[29]	Y. Zilbershtein et al. “Ingestible Device Platform for the Colon,” US Patent Application 20050266074.
[30]	M. P. Mintchev and O. Yadid-Pecht, “Pseudobezoar-basedintraluminal gastro-intestinal cleansing and biopsy,” Pending Canadian Patent application.
[31]	S. J. Heitman, R. J. HIlsden, F. Au, S. Dowden and B. J. Manns, “Colerectal Cancer Screening for Average Risk North Americans: An Economic Evaluation,” PLOS Medicine, Vol. 7, No. 11, 2010.
[32]	E. Gough, H. Shaikh and A. R. Manges, “Systematic Review of Intestinal Microbiota Transplantation (Fecal Bacteriotherapy) for Recurrent Clostridium Difficile Infection,” Clinical infectious diseases, Vol. 53, No. 10, 2011, pp. 994-1002. doi:10.1093/cid/cir632